Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5984215 | 0.92 | KDM4E (0.52) | KDM4ETSHRSMN1; SMN2HTTUSP2 | |
| SCHEMBL1817556 | 0.85 | TRPV4 (0.66) | KDM4ETSHRSMN1; SMN2HTTUSP2 | |
| SCHEMBL30002818 | 0.85 | TRPV4 (0.66) | KDM4ETSHRSMN1; SMN2HTTUSP2 | |
| SCHEMBL31481574 | 0.81 | KDM4E (0.59) | KDM4ETSHRSMN1; SMN2HTTUSP2 | |
| SCHEMBL17101695 | 0.81 | KDM4E (0.59) | KDM4ETSHRSMN1; SMN2HTTUSP2 | |
| SCHEMBL28755848 | 0.81 | TSHR (0.52) | KDM4ETSHRSMN1; SMN2HTTUSP2 | |
| SCHEMBL24314192 | 0.81 | TRPV4 (0.50) | KDM4ETSHRSMN1; SMN2HTTUSP2 | |
| SCHEMBL29580235 | 0.80 | SMN1; SMN2 (0.51) | KDM4ETSHRSMN1; SMN2HTTUSP2 | |
| SCHEMBL20304580 | 0.80 | SMN1; SMN2 (0.51) | KDM4ETSHRSMN1; SMN2HTTUSP2 | |
| Hydrochloric Acid SCHEMBL28106471 | 0.80 | KDM4E (0.58) | KDM4ETSHRSMN1; SMN2HTTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| WO-2025136811-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | IDEAYA BIOSCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025100970-A1 | TNAP INHIBITORY COMPOUND AND USE THEREOF | 주식회사 레드엔비아 | 2025-05-15 | — | — | WO | disclosed |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
| WO-2025070390-A1 | METHOD FOR PRODUCING N-PYRIDYLSULFONAMIDE COMPOUND, PYRIDINE COMPOUND, AND CRYSTAL OF N-PYRIDYLSULFONAMIDE COMPOUND | 第一三共株式会社 | 2025-04-03 | — | — | WO | disclosed |
| CN-119735529-A | Benzamide compound and application thereof in preparation of sensitizer of pseudomonas aeruginosa inhibitor | 海南大学 | 2025-04-01 | — | — | CN | disclosed |
| CN-118359542-A | Polysubstituted pyrazole compound and preparation method and application thereof | 甫康（上海）健康科技有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4385989-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117597341-A | Sulfonamide derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1660431-B1 | PHENOXYACETIC ACID DERIVATIVES | ASTRAZENECA AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1809619-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006047302-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | KDM4E 3979/4885TSHR 1115/4885SMN1; SMN2 2140/4885 |
| US-20060293352-A1 | Phenoxiacetic acid derivatives | HRH2, HRH1, HCAR2 | KDM4E 1701/4885TSHR 655/4885SMN1; SMN2 4388/4885 |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | GALR1, GALR3, GALR2 | KDM4E 2832/4885TSHR 156/4885SMN1; SMN2 1898/4885 |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | GALR1, GALR3, GALR2 | KDM4E 2832/4885TSHR 156/4885SMN1; SMN2 1898/4885 |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, NUDT1, NT5C2 | KDM4E 2782/4885TSHR 3929/4885SMN1; SMN2 1359/4885 |
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SULT2A1, KAT8, TST | KDM4E 474/4885TSHR 3574/4885SMN1; SMN2 4679/4885 |
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | KDM4E 844/4885TSHR 4151/4885SMN1; SMN2 3192/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | KDM4E 3107/4885TSHR 1140/4885SMN1; SMN2 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.